UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2024

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                             to                            

 

Commission file number: 000-49671

 

MODULAR MEDICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   87-0620495
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification No.)

 

10740 Thornmint Road, San Diego, CA 92127
(Address of Principal Executive Offices) (Zip Code)

 

(858) 800-3500
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock Par Value $.001 per Share   MODD   The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

☐ Yes ☒ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated Filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

☐ Yes ☒ No

 

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 32,561,407 as of August 5, 2024.

 

 

 

 

 

 

MODULAR MEDICAL, INC.

 

FORM 10-Q

JUNE 30, 2024

 

TABLE OF CONTENTS

 

PART I — FINANCIAL INFORMATION 1
     
Item 1. Financial Statements (Unaudited): 1
     
  Condensed Consolidated Balance Sheets as of June 30, 2024 and March 31, 2024 1
     
  Condensed Consolidated Statements of Operations for the three months ended June 30, 2024 and June 30, 2023 2
     
  Condensed Consolidated Statements of Stockholders’ Equity for the three months ended June 30, 2024 and 2023 3
     
  Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2024 and 2023 4
     
  Notes to Condensed Consolidated Financial Statements 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 17
     
Item 4. Controls and Procedures 17
     
PART II — OTHER INFORMATION 18
     
Item 1. Legal Proceedings 18
     
Item 1A. Risk Factors 18
     
Item 2. Unregistered Sales of Equity Securities 18
     
Item 3. Defaults Upon Senior Securities 18
     
Item 4. Mine Safety Disclosures 18
     
Item 5. Other Information 18
     
Item 6. Exhibits 19
     
  Signatures 20

 

i

 

  

Part I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Modular Medical, Inc.
Condensed Consolidated Balance Sheets

(In thousands, except par value)

 

   June 30,
2024
(Unaudited)		   March 31,
2024		 
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents  $5,052   $9,232 
Prepaid expenses and other   355    465 
TOTAL CURRENT ASSETS   5,407    9,697 
           
Property and equipment, net   3,619    2,975 
Right of use asset, net   1,046    1,135 
TOTAL ASSETS  $10,072   $13,807 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES          
Accounts payable  $461   $802 
Accrued expenses   495    280 
Short-term lease liabilities   386    373 
TOTAL CURRENT LIABILITIES   1,342    1,455 
           
Long-term lease liabilities   714    817 
TOTAL LIABILITIES   2,056    2,272 
           
Commitments and Contingencies (Note 7)   
 
    
 
 
           
STOCKHOLDERS’ EQUITY          
Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding   
—
    
—
 
Common Stock, $0.001 par value, 100,000 shares authorized; 32,561 and 32,464 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively   32    32 
Additional paid-in capital   78,050    77,432 
Accumulated deficit   (70,066)   (65,929)
TOTAL STOCKHOLDERS’ EQUITY   8,016    11,535 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $10,072   $13,807 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1

 

 

Modular Medical, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

(In thousands, except per share data)

 

   Three Months Ended
June 30,		 
   2024   2023 
Operating expenses        
Research and development  $3,205   $2,768 
General and administrative   1,015    983 
Total operating expenses   4,220    3,751 
Loss from operations   (4,220)   (3,751)
           
Other income   83    14 
           
Net loss  $(4,137)  $(3,737)
           
Net loss per share          
Basic and diluted
  $(0.12)  $(0.22)
           
Shares used in computing net loss per share          
Basic and diluted
   33,884    17,099 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2

 

 

Modular Medical, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)

(In thousands)

 

           Additional         
   Common Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Equity 
Balance as of March 31, 2024   32,464   $32   $77,432   $(65,929)  $11,535 
Shares issued for services   10    
—
    15    
—
    15 
Exercise of warrants   55    
—
    68    
—
    68 
Issuances under equity incentive plan   32    
—
    6    
—
    6 
Stock-based compensation   —    
—
    529    
—
    529 
Net loss   —    
—
    
—
    (4,137)   (4,137)
Balance as of June 30, 2024   32,561   $32   $78,050   $(70,066)  $8,016 

  

           Additional         
   Common Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Equity 
Balance as of March 31, 2023   10,949   $11   $53,524   $(48,459)  $5,076 
Issuance of common stock and warrants in equity offering, net   10,139    10    9,723    
—
    9,733 
Issuances under equity incentive plan   7    
—
    6    
—
    6 
Stock-based compensation   —    
—
    478    
—
    478 
Net loss   —    
—
    
—
    (3,737)   (3,737)
Balance as of June 30, 2023   21,095   $21   $63,731   $(52,196)  $11,556 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

Modular Medical, Inc.
Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

   Three Months Ended
June 30,		 
   2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss  $(4,137)  $(3,737)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation expense   535    484 
Depreciation and amortization   196    58 
Shares for services   5    5 
Other   1    
—
 
Changes in assets and liabilities:          
Prepaid expenses and other assets   (22)   (40)
Lease right-of-use asset   90    83 
Accounts payable and accrued expenses   (126)   46 
Change in lease liability   (90)   (106)
Net cash used in operating activities   (3,548)   (3,207)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchases of property and equipment   (842)   (373)
Net cash used in investing activities   (842)   (373)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from exercise of common stock purchase warrants   210    
—
 
Proceeds from issuance of common stock and warrants, net   
—
    9,733 
Net cash provided by financing activities   210    9,733 
           
Net increase (decrease) in cash and cash equivalents   (4,180)   6,153 
           
Cash and cash equivalents at beginning of period   9,232    3,799 
           
Cash and cash equivalents at end of period  $5,052   $9,952 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

MODULAR MEDICAL, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

 

NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras), and changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.

 

The Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the MODD1. In March 2024, the Company received comments from the FDA on its submission, and the Company responded to those comments in August 2024.

 

Liquidity and Going Concern

 

The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 

5

 

 

Basis of Presentation

 

The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.

 

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period.

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.

 

Reportable Segment

 

The Company operates in one business segment and uses one measurement of profitability for its business.

 

Research and Development

 

The Company expenses research and development expenditures as incurred.

  

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.

 

6

 

 

Risks and Uncertainties

 

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business.

  

Cash and Cash Equivalents

 

Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service.

 

Fair Value of Financial Instruments

 

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

 

  ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

 

  ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

  ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

 

Leases

 

The Company’s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

 

7

 

 

Stock-Based Compensation

 

The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.

 

Per-Share Amounts

 

Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.

  

For the three months ended June 30, 2024 and 2023, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).

 

   Three Months Ended
June 30,		 
   2024   2023 
Options to purchase common stock   4,322    2,824 
Unvested restricted stock units   167    
—
 
Common stock purchase warrants   11,173    11,997 
Total   15,662    14,821 

 

Reclassifications

 

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

 

Comprehensive Loss

 

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30, 2024 and 2023, the Company’s comprehensive loss was the same as its net loss.

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.

 

8

 

 

NOTE 2 – CONSOLIDATED BALANCE SHEET DETAIL

 

  

June 30,

2024

  

March 31,

2024 

 
   (in thousands) 
Property and equipment, net        
Machinery and equipment  $4,082   $3,209 
Computer equipment and software   66    66 
Construction-in-process   250    283 
Leasehold improvements   33    33 
Office equipment   46    63 
    4,477    3,654 
Less:  accumulated depreciation and amortization   (858)   (679)
Total  $3,619   $2,975 

 

  

June 30,

2024

  

March 31,

2024

 
   (in thousands) 
Accrued expenses        
Accrued wages and employee benefits  $296   $243 
Other   199    37 
Total  $495   $280 

 

NOTE 3 – LEASES

  

Thornmint Road, San Diego, CA 

 

The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 8%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the operating lease.

 

Future minimum payments under the facility operating lease, as of June 30, 2024, are listed in the table below (in thousands).

 

Annual Fiscal Years    
2025  $340 
2026   470 
2027   405 
Total future lease payments  $1,215 
Less:  Imputed interest   (115)
Present value of lease liability  $1,100 

 

Cash paid for amounts included in the measurement of lease liabilities was approximately $112,000 and $149,000 for the three months ended June 30, 2024 and 2023, respectively. Rent expense was approximately $112,000 for each of the three month periods ended June 30, 2024 and 2023, respectively.

 

9

 

 

NOTE 4 – STOCKHOLDERS’ EQUITY

 

ATM Offering

 

In November 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, for aggregate gross proceeds of up to $6,500,000 through an “at the market offering” program under which Leerink will act as sales agent or principal. The ATM Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at any time, suspend solicitation and offers under the ATM Agreement.

 

Warrants

 

As of June 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands):

 

   Number of
Shares		   Exercise
Price		   Expiration
Balance as of March 31, 2024   12,521         
Warrants exercised   (55)  $1.22   May 2028
Balance as of June 30, 2024   12,466         
              
As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):
              
Type  Number of
Shares		   Exercise
Price		   Expiration
Common stock   1,348   $0.01   —
Common stock   4,421    1.22   May 2028
Common stock   535    1.32   May 2027
Common stock   768    6.00   January 2027 - February 2027
Common stock   4,011    6.60   February 2027
Common stock   1,438   $6.60   November 2027
Total   12,521         

 

The 1,348,000 pre-funded warrants with an exercise price of $0.01 per share were included in the weighted average shares outstanding calculation for each of the three-month periods ended June 30, 2024 and 2023. At March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024 and was collected during the three months ended June 30, 2024.

 

Other

 

During the three months ended June 30, 2024, the Company issued 10,000 shares of common stock with a fair value of approximately $15,000 to a service provider.

 

10

 

 

NOTE 5 – STOCK-BASED COMPENSATION

 

Amended 2017 Equity Incentive Plan

 

In October 2017, the Board approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Company’s stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board. 

 

Stock-Based Compensation Expense

 

Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of June 30, 2024, the unamortized compensation cost related to stock options was approximately $2,262,000 and is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.

 

In October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock options for 909,533 shares, which are subject to vesting based upon the achievement of certain performance milestones by the Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were granted under part one of the Bonus Program, vested upon the Company’s submission to the FDA. As of June 30, 2024, the Company had not commenced expense recognition of 242,307 (net of forfeitures) of the options, which were granted under part two of the Bonus Program, based on its assessment of the probability of achievement of the applicable performance requirements.

 

The weighted-average grant date fair value of options granted was $1.33 and $1.00 per share for the three months ended June 30, 2024 and 2023, respectively. The following assumptions were used in the fair-value method calculations:

 

   Three Months Ended
June 30,		 
   2024   2023 
Risk-free interest rates  4.33% -  4.43%   3.51% - 4.13% 
Volatility  118% - 123%   83% - 152% 
Expected life (years)  5.0 - 5.7   5.0 - 6.1 

 

The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.

 

The following table summarizes the activity in the shares available for grant under the Plan during the three months ended June 30, 2024:

 

       Options Outstanding 
           Weighted 
   Shares       Average 
   Available   Number of   Exercise 
   for Grant   Shares   Prices 
Balance at March 31, 2024   3,648,651    3,689,341   $3.70 
Share awards   (3,875)   
—
    1.56 
Options granted   (682,375)   682,375    1.52 
Options exercised   
—
    (7,530)   1.08 
Options cancelled and returned to the Plan   42,230    (42,230)   2.62 
Balance at June 30, 2024   3,004,631    4,321,956   $3.36 

 

11

 

 

A stock option was exercised on a cashless basis for 7,530 shares of common stock during the three months ended June 30, 2024. There were no stock options exercised during the three months ended June 30, 2023. During the three months ended June 30, 2024 and 2023, the Company awarded 3,875 and 6,375 shares, respectively, to its non-employee directors under the Company’s outside director compensation plan. For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $6,000 and $5,900, respectively.

 

A summary of restricted stock unit (RSU) activity under the Plan is presented below.

 

       Weighted
Average 		 
   Number of
Shares		   Grant-Date
Fair Value		 
Balance at March 31, 2024   187,499   $0.91 
Vested   (20,832)  $0.91 
Non-vested shares at June 30, 2024   166,667   $0.91 

 

The total intrinsic value of RSUs outstanding as of June 30, 2024 was approximately $263,000. The unamortized compensation cost at June 30, 2024 was approximately $153,000 related to RSUs and is expected to be recognized as expense over a period of approximately two years.

 

The following table summarizes the range of outstanding and exercisable options as of June 30, 2024:

 

   Options Outstanding   Options Exercisable 
Range of Exercise Price  Number
Outstanding		   Weighted
Average
Remaining
Contractual
Life
(in Years)		   Weighted
Average
Exercise
Price		   Number
Exercisable		   Weighted
Average
Exercise
Price		   Aggregate
Intrinsic
value		 
$0.93 - $2.00   2,872,922    8.46   $1.49    1,564,467   $1.51   $369,936 
$3.95 - $7.51   940,367    6.94   $5.29    807,756   $5.46    
—
 
$8.61 - $17.70   508,667    6.98   $10.53    485,934   $10.53    
—
 
$0.93 - $17.70   4,321,956    7.96   $3.38    2,858,157   $4.16    
—
 

 

The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option.

 

NOTE 6 – INCOME TAXES

 

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.

 

The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2023 may be subject to examination by the U.S. federal and state tax authorities. As of June 30, 2024, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

 

12

 

 

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

Litigations, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

 

Indemnification

 

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the three months ended June 30, 2024 and 2023 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.

 

Purchase Obligations

 

The Company’s primary purchase obligations include purchase orders for machinery and equipment. At June 30, 2024, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $768,000.

In December 2023, the Company signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of June 30, 2024, the Company had a remaining obligation under the device integration agreement of approximately $400,000 over three years for technology license fees.

 

NOTE 8 – RELATED PARTY TRANSACTIONS

 

A family member of one of the Company’s executive officers is an employee of the Company. During the three months ended June 30, 2024 and 2023, the Company paid the family member approximately $57,300 and $34,800, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period.

 

NOTE 9 – SUBSEQUENT EVENTS

 

On August 2, 2024, 242,307 outstanding options, which were granted under part two of the Bonus Program, were cancelled, as the applicable performance requirements had not been achieved.

 

13

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this Quarterly Report on Form 10-Q (this Report). This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on June 21, 2024 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2024. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors including, without limitation, the direct and indirect effects of coronavirus disease 2019, or COVID-19, as well as inflationary risks, including the risk that the cost of certain of the Company’s components is increasing, and related issues that may arise therefrom. Many of those factors are outside of our control and could cause actual results to differ materially from those expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

 

Our fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). Unless the context requires otherwise, references to “we,” “us,” “our,” and the “Company” refer to Modular Medical, Inc. and its consolidated subsidiary.

 

Company Overview

 

We are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our initial product, the MODD1, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification to the United States Food and Drug Administration (“FDA”) for our MODD1 insulin pump. In March 2024, we

received comments from the FDA, and we submitted a response to the FDA’s comments in August 2024.

 

In February 2024, we completed a firm commitment underwritten offering and sold to the underwriter 9,090,910 shares of our common stock at a price of $1.10 per share (the 2024 Offering). We received aggregate proceeds of approximately $10.0 million before deducting underwriting discounts and commissions and other offering expenses. We also granted the underwriter a 30-day option to purchase up to an additional 1,321,989 shares of common stock to cover over allotments, if any. In March 2024, the underwriter exercised this option in full and purchased the additional securities for additional aggregate proceeds to us of approximately $1.5 million, before deducting underwriting discounts and commissions and other offering expenses. Historically, we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible promissory notes. Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued exists. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations. If we are unable to secure additional capital, we will be required to curtail our research and development initiatives and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the consolidated financial statements in Item 1 of this Report and under Liquidity below. 

 

14

 

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended March 31, 2024. As of June 30, 2024, there have been no material changes to our significant accounting policies and estimates.

 

Results of Operations

 

Research and Development

 

   Three months ended
June 30,		   Change 
   2024   2023   2023 to 2024 
   (dollar amounts in thousands) 
Research and development  $3,205   $2,768   $437    15.8%

 

Our research and development, or R&D, expenses include personnel, consulting, testing, materials and supplies, depreciation and amortization and other operational costs associated with the pre-FDA clearance production of our insulin pump product. We expense R&D costs as they are incurred.

 

Research and development, or R&D, expenses increased for fiscal 2025 compared with the same period of fiscal 2024, primarily due to increased employee-related costs of approximately $0.2 million, an increase of approximately $0.2 million in consulting costs, an increase in travel-related costs of approximately $0.1 million and an increase in depreciation expense of approximately $0.1 million. These increases were partially offset by an approximately $0.2 million decrease in material and supplies costs. Our full-time R&D employee headcount increased to 36 at June 30, 2024 from 34 at June 30, 2023. R&D expenses included stock-based compensation expenses of approximately $0.4 million for each of the three-month periods ended June 30, 2024 and June 30, 2023, respectively. We expect research and development expenses to remain consistent and then increase in the second half of fiscal 2025.

 

15

 

 

General and Administrative

 

   Three months ended
June 30,		   Change 
   2024   2023   2023 to 2024 
   (dollar amounts in thousands) 
General and administrative  $1,015   $983   $32    3.3%

 

General and administrative, or G&A, expenses consist primarily of personnel and related overhead costs for facilities, finance, human resources, legal, marketing and general management.

 

G&A expenses increased for the three months ended June 30, 2024 compared with the same period of 2023, primarily as a result of an increase in legal and professional services expenses of approximately $0.1 million, partially offset by decreases in facility-related costs of and other administrative expenses. G&A expenses included stock-based compensation expenses of approximately $0.2 million and $0.1 million for the three months ended June 30, 2024 and June 30, 2023, respectively. We expect G&A expenses to remain consistent and then begin to increase in the second half of fiscal 2025.

 

Liquidity and Capital Resources; Changes in Financial Condition 

 

We do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating losses and negative cash flows in each year due to costs incurred in connection with R&D activities and G&A expenses associated with our operations. For the three months ended June 30, 2024 and year ended March 31, 2024, we incurred net losses of approximately $4.1 million and $17.5 million, respectively. At June 30, 2024, we had a cash balance of $5.1 million and an accumulated deficit of approximately $70 million. When considered with our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our operating needs include the planned costs to operate our business, including amounts required to fund continued research and development activities, working capital and capital expenditures. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support our future operations. Recently, during the three months ended March 31, 2024, we completed an offering of shares of common stock for net proceeds of approximately $10.3 million, which includes the proceeds from the underwriter’s exercise of the overallotment. In November 2023, we entered into a Sales Agreement (the “ATM Agreement”) with Leerink Partners LLC (“Leerink”) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, for aggregate gross proceeds of up to $6.5 million (subject to availability on our shelf registration statement) through an “at the market offering” program under which Leerink will act as sales agent or principal. In January 2024, we sold 153,879 shares of common stock for net proceeds of approximately $0.3 million under the ATM Agreement. Subject to market conditions, we expect to resume sales under the ATM during the remainder of fiscal 2025, subject to market conditions. In addition, since December 2023, we received a total of approximately $1.0 million of proceeds from the exercise of common stock purchase warrants issued in a public offering we completed in May 2023. Our future capital requirements and the adequacy of our available funds will depend on many factors, including, without limitation, our ability to successfully commercialize our product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product offerings. If we are unable to secure additional capital timely, we may be required to curtail R&D initiatives, reduce headcount and take additional measures to reduce costs in order to conserve our cash.

 

For the three months ended June 30, 2024, we used approximately $3.5 million of cash in operating activities, which primarily resulted from our net loss of approximately $4.1 million and net changes in operating assets and liabilities of approximately $0.1 million, as adjusted for stock-based compensation expenses of approximately $0.5 million, depreciation and amortization expenses of approximately $0.2 million and other immaterial adjustments. For the three months ended June 30, 2023, we used approximately $3.2 million in operating activities, which primarily resulted from our net loss of approximately $3.7 million, as adjusted for stock-based compensation expenses of approximately $0.5 million and depreciation and amortization expenses of approximately $0.1 million, which was partially offset by other immaterial adjustments. 

 

For the three months ended June 30, 2024 and 2023, cash used in investing activities of approximately $0.8 million and $0.4 million, respectively, was for the purchase of property and equipment.

 

16

 

 

Cash provided by financing activities of approximately $0.2 million for the three months ended June 30, 2024 was attributable to proceeds from the exercise of common stock purchase warrants. Cash provided by financing activities of $9.7 million for the three months ended June 30, 2023 was attributable to net proceeds from the issuance of common stock and common stock purchase warrants in a public offering, net of underwriting fees and issuance costs.

 

Purchase Obligations

 

Our primary purchase obligations include purchase orders for machinery and equipment. At June 30, 2024, we had outstanding purchase orders for machinery and equipment and related expenditures of approximately $0.8 million.

 

In December 2023, we signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of June 30, 2024, we had a remaining obligation under the device integration agreement of approximately $0.4 million over three years for technology license fees.

 

Recently Issued Accounting Pronouncements

 

Recently issued accounting pronouncements are detailed in Note 1 in the Notes to the Condensed Consolidated Financial Statements included in Item 1 of this Report.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures.

 

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

 

Under the supervision and with the participation of our management, including our Chief Executive Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of June 30, 2024, our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting.

 

During the three months ended June 30, 2024, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

17

 

  

Part II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. To our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of us or our subsidiary, threatened against or affecting us, our common stock, our subsidiary or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors

 

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. There are no material changes to the risk factors set forth under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2024, which we filed with the SEC on June 21, 2024.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Recent Sales of Unregistered Securities

 

On June 28, 2024, we issued 20,832 shares to one of our non-employee directors upon vesting of a restricted stock unit award granted under our Amended and Restated 2017 Equity Incentive Plan. On April 9, 2024 we issued 10,000 shares of our common stock to a service provider. The aforementioned issuances were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation D of the Securities Act.

 

Item 3. Defaults Upon Senior Securities

 

There has been no default in the payment of principal, interest, or a sinking or purchase fund installment, or any other material default, with respect to any indebtedness of ours.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

18

 

 

Item 6. Exhibits

 

Exhibit       Reference       Filed or
Furnished
Number   Exhibit Description   Form   Exhibit   Filing Date   Herewith
10.1   Third Amendment to Employment Agreement between the Registrant and Paul DiPerna   8-K   10.1   04/10/2024    
31.1   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002               X
31.2   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002               X
32.1   Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002               X
101   The following financial information from Modular Medical, Inc.’s quarterly report on Form 10-Q for the period ended June 30, 2024, filed with the SEC on August 9, 2024, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Operations for the three months ended June 30, 2024 and 2023, (ii) the Condensed Consolidated Balance Sheets as of June 30 2024 and March 31, 2024, (iii) the Condensed Consolidated Statements of Stockholders’ Equity for the three months ended June 30, 2024 and 2023, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2024 and 2023, and (v) Notes to Condensed Consolidated Financial Statements.               X
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).               X

 

19

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MODULAR MEDICAL, INC.
     
Date: August 13, 2024 By: /s/ James E. Besser
    James E. Besser
    Chief Executive Officer
    (Principal Executive Officer)
   
  By: /s/ Paul DiPerna
    Paul DiPerna
    Chairman, President, Chief Financial Officer and Treasurer
    (Principal Financial Officer)

 

 

20

 

0.12 0.22 17099000 33884000 false --03-31 Q1 2025 0001074871 0001074871 2024-04-01 2024-06-30 0001074871 2024-08-05 0001074871 2024-06-30 0001074871 2024-03-31 0001074871 2023-04-01 2023-06-30 0001074871 us-gaap:CommonStockMember 2024-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001074871 us-gaap:RetainedEarningsMember 2024-03-31 0001074871 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001074871 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001074871 us-gaap:CommonStockMember 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001074871 us-gaap:RetainedEarningsMember 2024-06-30 0001074871 us-gaap:CommonStockMember 2023-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001074871 us-gaap:RetainedEarningsMember 2023-03-31 0001074871 2023-03-31 0001074871 us-gaap:CommonStockMember 2023-04-01 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2024-06-30 0001074871 us-gaap:RetainedEarningsMember 2023-04-01 2024-06-30 0001074871 2023-04-01 2024-06-30 0001074871 us-gaap:CommonStockMember 2023-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001074871 us-gaap:RetainedEarningsMember 2023-06-30 0001074871 2023-06-30 0001074871 srt:MinimumMember 2024-06-30 0001074871 srt:MaximumMember 2024-06-30 0001074871 us-gaap:StockOptionMember 2024-04-01 2024-06-30 0001074871 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2024-04-01 2024-06-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2023-04-01 2023-06-30 0001074871 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001074871 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-06-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001074871 us-gaap:ComputerEquipmentMember 2024-06-30 0001074871 us-gaap:ComputerEquipmentMember 2024-03-31 0001074871 us-gaap:ConstructionInProgressMember 2024-06-30 0001074871 us-gaap:ConstructionInProgressMember 2024-03-31 0001074871 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001074871 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001074871 us-gaap:OfficeEquipmentMember 2024-06-30 0001074871 us-gaap:OfficeEquipmentMember 2024-03-31 0001074871 modd:ThornmintRoadSanDiegoCAMember 2024-06-30 0001074871 2023-02-01 2023-02-01 0001074871 2023-02-01 0001074871 2023-11-30 2023-11-30 0001074871 us-gaap:WarrantMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001074871 us-gaap:WarrantMember 2024-03-31 0001074871 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001074871 us-gaap:WarrantMember 2024-06-30 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-03-31 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2024-03-31 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2024-03-31 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2024-03-31 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2024-03-31 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2024-03-31 2024-03-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2017-10-31 2017-10-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2020-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2021-08-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-02-28 0001074871 modd:MilestoneBonusProgramMember 2023-10-31 2023-10-31 0001074871 2024-01-31 2024-01-31 0001074871 us-gaap:StockCompensationPlanMember 2024-04-01 2024-06-30 0001074871 us-gaap:StockCompensationPlanMember 2023-04-01 2023-06-30 0001074871 modd:NonemployeeDirectorsMember 2024-04-01 2024-06-30 0001074871 modd:NonemployeeDirectorsMember 2023-04-01 2023-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001074871 srt:MinimumMember 2024-04-01 2024-06-30 0001074871 srt:MaximumMember 2024-04-01 2024-06-30 0001074871 srt:MinimumMember 2023-04-01 2023-06-30 0001074871 srt:MaximumMember 2023-04-01 2023-06-30 0001074871 us-gaap:RestrictedStockMember 2024-03-31 0001074871 us-gaap:RestrictedStockMember 2024-04-01 2024-06-30 0001074871 us-gaap:RestrictedStockMember 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001074871 srt:MinimumMember modd:ZeroPointNineThreeToTwoPointZeroZeroMember 2024-06-30 0001074871 srt:MaximumMember modd:ZeroPointNineThreeToTwoPointZeroZeroMember 2024-06-30 0001074871 modd:ZeroPointNineThreeToTwoPointZeroZeroMember 2024-06-30 0001074871 modd:ZeroPointNineThreeToTwoPointZeroZeroMember 2024-04-01 2024-06-30 0001074871 srt:MinimumMember modd:ThreePointNineFiveToSeveenPointFiveOneMember 2024-06-30 0001074871 srt:MaximumMember modd:ThreePointNineFiveToSeveenPointFiveOneMember 2024-06-30 0001074871 modd:ThreePointNineFiveToSeveenPointFiveOneMember 2024-06-30 0001074871 modd:ThreePointNineFiveToSeveenPointFiveOneMember 2024-04-01 2024-06-30 0001074871 srt:MinimumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-06-30 0001074871 srt:MaximumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-06-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-06-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-04-01 2024-06-30 0001074871 srt:MinimumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-06-30 0001074871 srt:MaximumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-06-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-06-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-04-01 2024-06-30 0001074871 modd:DeviceIntegrationAgreementMember 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001074871 us-gaap:SubsequentEventMember 2024-08-02 xbrli:shares iso4217:USD iso4217:USD xbrli:shares modd:segment xbrli:pure

Exhibit 31.1

 

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, James E. Besser, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended June 30, 2024;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

(d)Disclosed in this report any change in the registrant’s internal controls over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

/s/ James E. Besser   Date: August 13, 2024
James E. Besser    
Chief Executive Officer    

 

Exhibit 31.2

 

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Paul M. DiPerna, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended June 30, 2024;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

(d)Disclosed in this report any change in the registrant’s internal controls over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

/s/ Paul M. DiPerna   Date: August 13, 2024
Paul M. DiPerna    
Chairman, President, Chief Financial Officer and Treasurer    

Exhibit 32.1

 

CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Modular Medical, Inc. (the “Company”) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of James E. Besser, Chief Executive Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of the Company.

 

By: /s/ James E. Besser   Date: August 13, 2024
  James E. Besser    
  Chief Executive Officer    

 

By: /s/ Paul M. DiPerna   Date: August 13, 2024
  Paul M. DiPerna    
  Chairman, President, Chief Financial Officer and Treasurer    

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

v3.24.2.u1
Cover - shares
 3 Months Ended
Jun. 30, 2024
Aug. 05, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current No  
Amendment Flag false  
Document Period End Date Jun. 30, 2024  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Entity Information [Line Items]    
Entity Registrant Name MODULAR MEDICAL, INC.  
Entity Central Index Key 0001074871  
Entity File Number 000-49671  
Entity Tax Identification Number 87-0620495  
Entity Incorporation, State or Country Code NV  
Current Fiscal Year End Date --03-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 10740 Thornmint Road  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92127  
Entity Phone Fax Numbers [Line Items]    
City Area Code (858)  
Local Phone Number 800-3500  
Entity Listings [Line Items]    
Title of 12(b) Security Common Stock Par Value $.001 per Share  
Trading Symbol MODD  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   32,561,407
v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2024
Mar. 31, 2024
CURRENT ASSETS    
Cash and cash equivalents $ 5,052 $ 9,232
Prepaid expenses and other 355 465
TOTAL CURRENT ASSETS 5,407 9,697
Property and equipment, net 3,619 2,975
Right of use asset, net 1,046 1,135
TOTAL ASSETS 10,072 13,807
CURRENT LIABILITIES    
Accounts payable 461 802
Accrued expenses 495 280
Short-term lease liabilities 386 373
TOTAL CURRENT LIABILITIES 1,342 1,455
Long-term lease liabilities 714 817
TOTAL LIABILITIES 2,056 2,272
Commitments and Contingencies (Note 7)
STOCKHOLDERS’ EQUITY    
Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding
Common Stock, $0.001 par value, 100,000 shares authorized; 32,561 and 32,464 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 32 32
Additional paid-in capital 78,050 77,432
Accumulated deficit (70,066) (65,929)
TOTAL STOCKHOLDERS’ EQUITY 8,016 11,535
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 10,072 $ 13,807
v3.24.2.u1
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
shares in Thousands
Jun. 30, 2024
Mar. 31, 2024
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000 5,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 100,000 100,000
Common stock, shares issued 32,561 32,464
Common stock, shares outstanding 32,561 32,464
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating expenses    
Research and development $ 3,205 $ 2,768
General and administrative 1,015 983
Total operating expenses 4,220 3,751
Loss from operations (4,220) (3,751)
Other income 83 14
Net loss $ (4,137) $ (3,737)
Net loss per share    
Basic (in Dollars per share) $ (0.12) $ (0.22)
Shares used in computing net loss per share    
Basic (in Shares) 33,884 17,099
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
shares in Thousands
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]    
Diluted net loss per share $ (0.12) $ (0.22)
Diluted shares used in computing net loss per share 33,884 17,099
v3.24.2.u1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Mar. 31, 2023 $ 11 $ 53,524 $ (48,459) $ 5,076
Balance (in Shares) at Mar. 31, 2023 10,949      
Net loss       (3,737)
Balance at Jun. 30, 2023 $ 21 63,731 (52,196) 11,556
Balance (in Shares) at Jun. 30, 2023 21,095      
Balance at Mar. 31, 2023 $ 11 53,524 (48,459) 5,076
Balance (in Shares) at Mar. 31, 2023 10,949      
Issuance of common stock and warrants in equity offering, net $ 10 9,723 9,733
Issuance of common stock and warrants in equity offering, net (in Shares) 10,139      
Issuances under equity incentive plan 6 6
Issuances under equity incentive plan (in Shares) 7      
Stock-based compensation 478 478
Net loss (3,737) (3,737)
Balance at Jun. 30, 2024 $ 32 78,050 (70,066) $ 8,016
Balance (in Shares) at Jun. 30, 2024 32,561     32,561
Balance at Mar. 31, 2024 $ 32 77,432 (65,929) $ 11,535
Balance (in Shares) at Mar. 31, 2024 32,464      
Shares issued for services 15 15
Shares issued for services (in Shares) 10      
Exercise of warrants 68 68
Exercise of warrants (in Shares) 55      
Issuances under equity incentive plan 6 6
Issuances under equity incentive plan (in Shares) 32      
Stock-based compensation 529 529
Net loss (4,137) (4,137)
Balance at Jun. 30, 2024 $ 32 $ 78,050 $ (70,066) $ 8,016
Balance (in Shares) at Jun. 30, 2024 32,561     32,561
v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (4,137) $ (3,737)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 535 484
Depreciation and amortization 196 58
Shares for services 5 5
Other 1
Changes in assets and liabilities:    
Prepaid expenses and other assets (22) (40)
Lease right-of-use asset 90 83
Accounts payable and accrued expenses (126) 46
Change in lease liability (90) (106)
Net cash used in operating activities (3,548) (3,207)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchases of property and equipment (842) (373)
Net cash used in investing activities (842) (373)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from exercise of common stock purchase warrants 210
Proceeds from issuance of common stock and warrants, net 9,733
Net cash provided by financing activities 210 9,733
Net increase (decrease) in cash and cash equivalents (4,180) 6,153
Cash and cash equivalents at beginning of period 9,232 3,799
Cash and cash equivalents at end of period $ 5,052 $ 9,952
v3.24.2.u1
The Company and Summary of Significant Accounting Policies
 3 Months Ended
Jun. 30, 2024
The Company and Summary of Significant Accounting Policies [Abstract]  
THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras), and changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.

 

The Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the MODD1. In March 2024, the Company received comments from the FDA on its submission, and the Company responded to those comments in August 2024.

 

Liquidity and Going Concern

 

The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 

Basis of Presentation

 

The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.

 

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period.

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.

 

Reportable Segment

 

The Company operates in one business segment and uses one measurement of profitability for its business.

 

Research and Development

 

The Company expenses research and development expenditures as incurred.

  

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.

 

Risks and Uncertainties

 

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business.

  

Cash and Cash Equivalents

 

Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service.

 

Fair Value of Financial Instruments

 

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

 

  ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

 

  ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

  ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.

 

Leases

 

The Company’s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

 

Stock-Based Compensation

 

The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.

 

Per-Share Amounts

 

Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.

  

For the three months ended June 30, 2024 and 2023, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).

 

   Three Months Ended
June 30,		 
   2024   2023 
Options to purchase common stock   4,322    2,824 
Unvested restricted stock units   167    
—
 
Common stock purchase warrants   11,173    11,997 
Total   15,662    14,821 

 

Reclassifications

 

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

 

Comprehensive Loss

 

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30, 2024 and 2023, the Company’s comprehensive loss was the same as its net loss.

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.
v3.24.2.u1
Consolidated Balance Sheet Detail
 3 Months Ended
Jun. 30, 2024
Consolidated Balance Sheet Detail [Abstract]  
CONSOLIDATED BALANCE SHEET DETAIL

NOTE 2 – CONSOLIDATED BALANCE SHEET DETAIL

 

  

June 30,

2024

  

March 31,

2024 

 
   (in thousands) 
Property and equipment, net        
Machinery and equipment  $4,082   $3,209 
Computer equipment and software   66    66 
Construction-in-process   250    283 
Leasehold improvements   33    33 
Office equipment   46    63 
    4,477    3,654 
Less:  accumulated depreciation and amortization   (858)   (679)
Total  $3,619   $2,975 

 

  

June 30,

2024

  

March 31,

2024

 
   (in thousands) 
Accrued expenses        
Accrued wages and employee benefits  $296   $243 
Other   199    37 
Total  $495   $280 
v3.24.2.u1
Leases
 3 Months Ended
Jun. 30, 2024
Leases [Abstract]  
LEASES

NOTE 3 – LEASES

  

Thornmint Road, San Diego, CA 

 

The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 8%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the operating lease.

 

Future minimum payments under the facility operating lease, as of June 30, 2024, are listed in the table below (in thousands).

 

Annual Fiscal Years    
2025  $340 
2026   470 
2027   405 
Total future lease payments  $1,215 
Less:  Imputed interest   (115)
Present value of lease liability  $1,100 

 

Cash paid for amounts included in the measurement of lease liabilities was approximately $112,000 and $149,000 for the three months ended June 30, 2024 and 2023, respectively. Rent expense was approximately $112,000 for each of the three month periods ended June 30, 2024 and 2023, respectively.
v3.24.2.u1
Stockholders’ Equity
 3 Months Ended
Jun. 30, 2024
Stockholders’ Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 4 – STOCKHOLDERS’ EQUITY

 

ATM Offering

 

In November 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, for aggregate gross proceeds of up to $6,500,000 through an “at the market offering” program under which Leerink will act as sales agent or principal. The ATM Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at any time, suspend solicitation and offers under the ATM Agreement.

 

Warrants

 

As of June 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands):

 

   Number of
Shares		   Exercise
Price		   Expiration
Balance as of March 31, 2024   12,521         
Warrants exercised   (55)  $1.22   May 2028
Balance as of June 30, 2024   12,466         
              
As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):
              
Type  Number of
Shares		   Exercise
Price		   Expiration
Common stock   1,348   $0.01   —
Common stock   4,421    1.22   May 2028
Common stock   535    1.32   May 2027
Common stock   768    6.00   January 2027 - February 2027
Common stock   4,011    6.60   February 2027
Common stock   1,438   $6.60   November 2027
Total   12,521         

 

The 1,348,000 pre-funded warrants with an exercise price of $0.01 per share were included in the weighted average shares outstanding calculation for each of the three-month periods ended June 30, 2024 and 2023. At March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024 and was collected during the three months ended June 30, 2024.

 

Other

 

During the three months ended June 30, 2024, the Company issued 10,000 shares of common stock with a fair value of approximately $15,000 to a service provider.
v3.24.2.u1
Stock-Based Compensation
 3 Months Ended
Jun. 30, 2024
Stock-Based Compensation [Abstract]  
STOCK-BASED COMPENSATION

NOTE 5 – STOCK-BASED COMPENSATION

 

Amended 2017 Equity Incentive Plan

 

In October 2017, the Board approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Company’s stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board. 

 

Stock-Based Compensation Expense

 

Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of June 30, 2024, the unamortized compensation cost related to stock options was approximately $2,262,000 and is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.

 

In October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock options for 909,533 shares, which are subject to vesting based upon the achievement of certain performance milestones by the Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were granted under part one of the Bonus Program, vested upon the Company’s submission to the FDA. As of June 30, 2024, the Company had not commenced expense recognition of 242,307 (net of forfeitures) of the options, which were granted under part two of the Bonus Program, based on its assessment of the probability of achievement of the applicable performance requirements.

 

The weighted-average grant date fair value of options granted was $1.33 and $1.00 per share for the three months ended June 30, 2024 and 2023, respectively. The following assumptions were used in the fair-value method calculations:

 

   Three Months Ended
June 30,		 
   2024   2023 
Risk-free interest rates  4.33% -  4.43%   3.51% - 4.13% 
Volatility  118% - 123%   83% - 152% 
Expected life (years)  5.0 - 5.7   5.0 - 6.1 

 

The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.

 

The following table summarizes the activity in the shares available for grant under the Plan during the three months ended June 30, 2024:

 

       Options Outstanding 
           Weighted 
   Shares       Average 
   Available   Number of   Exercise 
   for Grant   Shares   Prices 
Balance at March 31, 2024   3,648,651    3,689,341   $3.70 
Share awards   (3,875)   
—
    1.56 
Options granted   (682,375)   682,375    1.52 
Options exercised   
—
    (7,530)   1.08 
Options cancelled and returned to the Plan   42,230    (42,230)   2.62 
Balance at June 30, 2024   3,004,631    4,321,956   $3.36 

 

A stock option was exercised on a cashless basis for 7,530 shares of common stock during the three months ended June 30, 2024. There were no stock options exercised during the three months ended June 30, 2023. During the three months ended June 30, 2024 and 2023, the Company awarded 3,875 and 6,375 shares, respectively, to its non-employee directors under the Company’s outside director compensation plan. For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $6,000 and $5,900, respectively.

 

A summary of restricted stock unit (RSU) activity under the Plan is presented below.

 

       Weighted
Average 		 
   Number of
Shares		   Grant-Date
Fair Value		 
Balance at March 31, 2024   187,499   $0.91 
Vested   (20,832)  $0.91 
Non-vested shares at June 30, 2024   166,667   $0.91 

 

The total intrinsic value of RSUs outstanding as of June 30, 2024 was approximately $263,000. The unamortized compensation cost at June 30, 2024 was approximately $153,000 related to RSUs and is expected to be recognized as expense over a period of approximately two years.

 

The following table summarizes the range of outstanding and exercisable options as of June 30, 2024:

 

   Options Outstanding   Options Exercisable 
Range of Exercise Price  Number
Outstanding		   Weighted
Average
Remaining
Contractual
Life
(in Years)		   Weighted
Average
Exercise
Price		   Number
Exercisable		   Weighted
Average
Exercise
Price		   Aggregate
Intrinsic
value		 
$0.93 - $2.00   2,872,922    8.46   $1.49    1,564,467   $1.51   $369,936 
$3.95 - $7.51   940,367    6.94   $5.29    807,756   $5.46    
—
 
$8.61 - $17.70   508,667    6.98   $10.53    485,934   $10.53    
—
 
$0.93 - $17.70   4,321,956    7.96   $3.38    2,858,157   $4.16    
—
 

 

The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option.
v3.24.2.u1
Income Taxes
 3 Months Ended
Jun. 30, 2024
Income Taxes [Abstract]  
INCOME TAXES

NOTE 6 – INCOME TAXES

 

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.

 

The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2023 may be subject to examination by the U.S. federal and state tax authorities. As of June 30, 2024, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.
v3.24.2.u1
Commitments and Contingencies
 3 Months Ended
Jun. 30, 2024
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

Litigations, Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

 

Indemnification

 

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the three months ended June 30, 2024 and 2023 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.

 

Purchase Obligations

 

The Company’s primary purchase obligations include purchase orders for machinery and equipment. At June 30, 2024, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $768,000.

In December 2023, the Company signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of June 30, 2024, the Company had a remaining obligation under the device integration agreement of approximately $400,000 over three years for technology license fees.
v3.24.2.u1
Related Party Transactions
 3 Months Ended
Jun. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

 

A family member of one of the Company’s executive officers is an employee of the Company. During the three months ended June 30, 2024 and 2023, the Company paid the family member approximately $57,300 and $34,800, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period.
v3.24.2.u1
Subsequent Events
 3 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

 

On August 2, 2024, 242,307 outstanding options, which were granted under part two of the Bonus Program, were cancelled, as the applicable performance requirements had not been achieved.
v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 15 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Pay vs Performance Disclosure      
Net Income (Loss) $ (4,137) $ (3,737) $ (3,737)
v3.24.2.u1
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.2.u1
Accounting Policies, by Policy (Policies)
 3 Months Ended
Jun. 30, 2024
The Company and Summary of Significant Accounting Policies [Abstract]  
Liquidity and Going Concern

Liquidity and Going Concern

The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 
Basis of Presentation

Basis of Presentation

The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period.
Use of Estimates

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.
Reportable Segment

Reportable Segment

The Company operates in one business segment and uses one measurement of profitability for its business.
Research and Development

Research and Development

The Company expenses research and development expenditures as incurred.
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.

 
Risks and Uncertainties

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business.
Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Property and Equipment

Property and Equipment

Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

  ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
  ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.
Leases

Leases

The Company’s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

 
Stock-Based Compensation

Stock-Based Compensation

The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.
Per-Share Amounts

Per-Share Amounts

Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.

For the three months ended June 30, 2024 and 2023, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).

   Three Months Ended
June 30,		 
   2024   2023 
Options to purchase common stock   4,322    2,824 
Unvested restricted stock units   167    
—
 
Common stock purchase warrants   11,173    11,997 
Total   15,662    14,821 
Reclassifications

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.
Comprehensive Loss

Comprehensive Loss

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30, 2024 and 2023, the Company’s comprehensive loss was the same as its net loss.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.
v3.24.2.u1
The Company and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Jun. 30, 2024
The Company and Summary of Significant Accounting Policies [Abstract]  
Schedule of Diluted Net Loss Per Share For the three months ended June 30, 2024 and 2023, the following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).
   Three Months Ended
June 30,		 
   2024   2023 
Options to purchase common stock   4,322    2,824 
Unvested restricted stock units   167    
—
 
Common stock purchase warrants   11,173    11,997 
Total   15,662    14,821 
v3.24.2.u1
Consolidated Balance Sheet Detail (Tables)
 3 Months Ended
Jun. 30, 2024
Consolidated Balance Sheet Detail [Abstract]  
Schedule of Property and Equipment, Net
  

June 30,

2024

  

March 31,

2024 

 
   (in thousands) 
Property and equipment, net        
Machinery and equipment  $4,082   $3,209 
Computer equipment and software   66    66 
Construction-in-process   250    283 
Leasehold improvements   33    33 
Office equipment   46    63 
    4,477    3,654 
Less:  accumulated depreciation and amortization   (858)   (679)
Total  $3,619   $2,975 
Schedule of Accrued Expenses
  

June 30,

2024

  

March 31,

2024

 
   (in thousands) 
Accrued expenses        
Accrued wages and employee benefits  $296   $243 
Other   199    37 
Total  $495   $280 
v3.24.2.u1
Leases (Tables)
 3 Months Ended
Jun. 30, 2024
Leases [Abstract]  
Schedule of Future Minimum Payments Under the Facility Operating Lease Future minimum payments under the facility operating lease, as of June 30, 2024, are listed in the table below (in thousands).
Annual Fiscal Years    
2025  $340 
2026   470 
2027   405 
Total future lease payments  $1,215 
Less:  Imputed interest   (115)
Present value of lease liability  $1,100 
v3.24.2.u1
Stockholders’ Equity (Tables)
 3 Months Ended
Jun. 30, 2024
Stockholders’ Equity [Abstract]  
Schedule of Warrants Outstanding As of June 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands):
   Number of
Shares		   Exercise
Price		   Expiration
Balance as of March 31, 2024   12,521         
Warrants exercised   (55)  $1.22   May 2028
Balance as of June 30, 2024   12,466         
              
As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):
              
Type  Number of
Shares		   Exercise
Price		   Expiration
Common stock   1,348   $0.01   —
Common stock   4,421    1.22   May 2028
Common stock   535    1.32   May 2027
Common stock   768    6.00   January 2027 - February 2027
Common stock   4,011    6.60   February 2027
Common stock   1,438   $6.60   November 2027
Total   12,521         
v3.24.2.u1
Stock-Based Compensation (Tables)
 3 Months Ended
Jun. 30, 2024
Stock-Based Compensation [Abstract]  
Schedule of Assumptions were used in the Fair-Value Method The following assumptions were used in the fair-value method calculations:
   Three Months Ended
June 30,		 
   2024   2023 
Risk-free interest rates  4.33% -  4.43%   3.51% - 4.13% 
Volatility  118% - 123%   83% - 152% 
Expected life (years)  5.0 - 5.7   5.0 - 6.1 
Schedule of Summarizes the Activity in the Shares The following table summarizes the activity in the shares available for grant under the Plan during the three months ended June 30, 2024:
       Options Outstanding 
           Weighted 
   Shares       Average 
   Available   Number of   Exercise 
   for Grant   Shares   Prices 
Balance at March 31, 2024   3,648,651    3,689,341   $3.70 
Share awards   (3,875)   
—
    1.56 
Options granted   (682,375)   682,375    1.52 
Options exercised   
—
    (7,530)   1.08 
Options cancelled and returned to the Plan   42,230    (42,230)   2.62 
Balance at June 30, 2024   3,004,631    4,321,956   $3.36 

 
Schedule of RSU Activity under the Plan A summary of restricted stock unit (RSU) activity under the Plan is presented below.
       Weighted
Average 		 
   Number of
Shares		   Grant-Date
Fair Value		 
Balance at March 31, 2024   187,499   $0.91 
Vested   (20,832)  $0.91 
Non-vested shares at June 30, 2024   166,667   $0.91 
Schedule of Outstanding and Exercisable Options The following table summarizes the range of outstanding and exercisable options as of June 30, 2024:
   Options Outstanding   Options Exercisable 
Range of Exercise Price  Number
Outstanding		   Weighted
Average
Remaining
Contractual
Life
(in Years)		   Weighted
Average
Exercise
Price		   Number
Exercisable		   Weighted
Average
Exercise
Price		   Aggregate
Intrinsic
value		 
$0.93 - $2.00   2,872,922    8.46   $1.49    1,564,467   $1.51   $369,936 
$3.95 - $7.51   940,367    6.94   $5.29    807,756   $5.46    
—
 
$8.61 - $17.70   508,667    6.98   $10.53    485,934   $10.53    
—
 
$0.93 - $17.70   4,321,956    7.96   $3.38    2,858,157   $4.16    
—
 
v3.24.2.u1
The Company and Summary of Significant Accounting Policies (Details)
 3 Months Ended
Jun. 30, 2024
USD ($)
segment
The Company and Summary of Significant Accounting Policies [Line Items]  
Business segment (in segment) | segment 1
FDIC insured amount (in Dollars) | $ $ 250,000
Minimum [Member]  
The Company and Summary of Significant Accounting Policies [Line Items]  
Estimated useful lives 3 years
Maximum [Member]  
The Company and Summary of Significant Accounting Policies [Line Items]  
Estimated useful lives 5 years
v3.24.2.u1
The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share - shares
shares in Thousands
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive total 15,662 14,821
Options to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive total 4,322 2,824
Unvested restricted stock units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive total 167
Common stock purchase warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive total 11,173 11,997
v3.24.2.u1
Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net - USD ($)
$ in Thousands
Jun. 30, 2024
Mar. 31, 2024
Property and equipment, net    
Property and equipment, gross $ 4,477 $ 3,654
Less: accumulated depreciation and amortization (858) (679)
Total property and equipment, net 3,619 2,975
Machinery and equipment [Member]    
Property and equipment, net    
Property and equipment, gross 4,082 3,209
Computer equipment and software [Member]    
Property and equipment, net    
Property and equipment, gross 66 66
Construction-in-process [Member]    
Property and equipment, net    
Property and equipment, gross 250 283
Leasehold improvements [Member]    
Property and equipment, net    
Property and equipment, gross 33 33
Office equipment [Member]    
Property and equipment, net    
Property and equipment, gross $ 46 $ 63
v3.24.2.u1
Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses - USD ($)
$ in Thousands
Jun. 30, 2024
Mar. 31, 2024
Accrued expenses    
Accrued wages and employee benefits $ 296 $ 243
Other 199 37
Total accrued expenses $ 495 $ 280
v3.24.2.u1
Leases (Details) - USD ($)
 3 Months Ended
Feb. 01, 2023
Jun. 30, 2024
Jun. 30, 2023
Leases [Line Items]      
Rent expense $ 36,000 $ 112,000 $ 112,000
Annual rent increases percentage 4.00%    
Discount rate   8.00%  
Obtained a right-of-use asset   $ 1,560,000  
Cash paid   $ 112,000 $ 149,000
Thornmint Road, San Diego, CA [Member]      
Leases [Line Items]      
Lease term   48 months  
v3.24.2.u1
Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease
$ in Thousands
Jun. 30, 2024
USD ($)
Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract]  
2025 $ 340
2026 470
2027 405
Total future lease payments 1,215
Less: Imputed interest (115)
Present value of lease liability $ 1,100
v3.24.2.u1
Stockholders’ Equity (Details) - USD ($)
 3 Months Ended 12 Months Ended 15 Months Ended
Nov. 30, 2023
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Stockholders’ Equity [Line Items]          
Aggregate proceeds $ 6,500,000        
Compensation services equal percentage 3.00%        
Total warrants outstanding   1,348,000   1,348,000 1,348,000
Pre-funded warrants exercise price   $ 0.01   $ 0.01 $ 0.01
Issued for services   $ 15,000      
Warrant [Member]          
Stockholders’ Equity [Line Items]          
Total warrants outstanding   12,466,000 12,521,000 12,466,000  
Aggregate proceeds     $ 142,000    
Common Stock [Member]          
Stockholders’ Equity [Line Items]          
Issuance of common stock shares       10,139,000  
Issued for services        
Common Stock [Member] | Warrant [Member]          
Stockholders’ Equity [Line Items]          
Issuance of common stock shares   10,000      
Issued for services   $ 15,000      
v3.24.2.u1
Stockholders’ Equity (Details) - Schedule of Warrants Outstanding - Warrant [Member] - $ / shares
 3 Months Ended
Mar. 31, 2024
Jun. 30, 2024
Class of Warrant or Right [Line Items]    
Number of Shares, balance   12,521,000
Number of Shares, Common stock 12,521,000 12,466,000
Number of Shares, Warrants exercised   (55,000)
Exercise Price, Warrants exercised (in Dollars per share)   $ 1.22
Expiration, Warrants exercised   May 2028
Number of Shares, balance 12,521,000 12,466,000
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   1,348,000
Number of Shares, Common stock 1,348,000  
Exercise Price, Common stock (in Dollars per share) $ 0.01  
Expiration Dates, Common stock  
Number of Shares, balance 1,348,000  
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   4,421,000
Number of Shares, Common stock 4,421,000  
Exercise Price, Common stock (in Dollars per share) $ 1.22  
Expiration Dates, Common stock May 2028  
Number of Shares, balance 4,421,000  
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   535,000
Number of Shares, Common stock 535,000  
Exercise Price, Common stock (in Dollars per share) $ 1.32  
Expiration Dates, Common stock May 2027  
Number of Shares, balance 535,000  
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   768,000
Number of Shares, Common stock 768,000  
Exercise Price, Common stock (in Dollars per share) $ 6  
Expiration Dates, Common stock January 2027 - February 2027  
Number of Shares, balance 768,000  
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   4,011,000
Number of Shares, Common stock 4,011,000  
Exercise Price, Common stock (in Dollars per share) $ 6.6  
Expiration Dates, Common stock February 2027  
Number of Shares, balance 4,011,000  
Common stock [Member]    
Class of Warrant or Right [Line Items]    
Number of Shares, balance   1,438,000
Number of Shares, Common stock 1,438,000  
Exercise Price, Common stock (in Dollars per share) $ 6.6  
Expiration Dates, Common stock November 2027  
Number of Shares, balance 1,438,000  
v3.24.2.u1
Stock-Based Compensation (Details) - USD ($)
 3 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Oct. 31, 2017
Jun. 30, 2024
Jun. 30, 2023
Feb. 28, 2024
Jan. 31, 2023
Aug. 31, 2021
Jan. 31, 2020
Stock-Based Compensation [Line Items]                  
Contractual term       10 years          
Unamortized compensation cost (in Dollars)       $ 2,262,000          
Weighted average period       1 year 7 months 6 days          
Total number of options granted 625,326                
Number of option shares outstanding       242,307          
Option exercised       7,530          
Milestone Bonus Program [Member]                  
Stock-Based Compensation [Line Items]                  
Total number of options granted   909,533              
Stock-Based Compensation [Member]                  
Stock-Based Compensation [Line Items]                  
Fair value of stock options granted price (in Dollars per share)       $ 1.33 $ 1        
Restricted Stock Units (RSUs) [Member]                  
Stock-Based Compensation [Line Items]                  
Unamortized compensation cost (in Dollars)       $ 153,000          
Total intrinsic value (in Dollars)       $ 263,000          
Non-employee Directors [Member]                  
Stock-Based Compensation [Line Items]                  
Shares issued       3,875 6,375        
Stock-based compensation (in Dollars)       $ 6,000 $ 5,900        
2017 Equity Incentive Plan [Member]                  
Stock-Based Compensation [Line Items]                  
Shares approved under equity incentive plan     1,000,000            
Number of shares reserved           3,000,000 2,000,000 1,333,334 333,334
v3.24.2.u1
Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Minimum [Member]    
Schedule of Assumptions were used in the Fair-Value Method [Line Items]    
Risk-free interest rates 4.33% 3.51%
Volatility 118.00% 83.00%
Expected life (years) 5 years 5 years
Maximum [Member]    
Schedule of Assumptions were used in the Fair-Value Method [Line Items]    
Risk-free interest rates 4.43% 4.13%
Volatility 123.00% 152.00%
Expected life (years) 5 years 8 months 12 days 6 years 1 month 6 days
v3.24.2.u1
Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares - Restricted Stock Units (RSUs) [Member]
 3 Months Ended
Jun. 30, 2024
$ / shares
shares
Schedule of the Activity in the Shares [Line Items]  
Shares Available for Grant, Beginning Balance 3,648,651
Number of Shares, Beginning Balance 3,689,341
Weighted Average Exercise Price, Beginning Balance (in Dollars per share) | $ / shares $ 3.7
Shares Available for Grant, Share awards (3,875)
Number of Shares, Share awards
Weighted Average Exercise Price, Share awards (in Dollars per share) | $ / shares $ 1.56
Shares Available for Grant, Options granted (682,375)
Number of Shares, Options granted 682,375
Weighted Average Exercise Price, Options granted (in Dollars per share) | $ / shares $ 1.52
Shares Available for Grant, Options exercised
Number of Shares, Options exercised (7,530)
Weighted Average Exercise Price, Options exercised (in Dollars per share) | $ / shares $ 1.08
Shares Available for Grant, Options cancelled and returned to the Plan 42,230
Number of Shares, Options cancelled and returned to the Plan (42,230)
Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share) | $ / shares $ 2.62
Shares Available for Grant, Ending Balance 3,004,631
Number of Shares, Ending Balance 4,321,956
Weighted Average Exercise Price, Ending Balance (in Dollars per share) | $ / shares $ 3.36
v3.24.2.u1
Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan - Restricted Stock Units (RSUs) [Member]
 3 Months Ended
Jun. 30, 2024
$ / shares
shares
Schedule of RSU Activity Under the Plan [Line Items]  
Number of Shares, Beginning Balance | shares 187,499
Weighted Average Grant-Date Fair Value, Beginning Balance | $ / shares $ 0.91
Number of Shares, Vested | shares (20,832)
Weighted Average Grant- Date Fair Value, Vested | $ / shares $ 0.91
Number of Shares, Ending Balance | shares 166,667
Weighted Average Grant-Date Fair Value, Ending Balance | $ / shares $ 0.91
v3.24.2.u1
Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options
 3 Months Ended
Jun. 30, 2024
USD ($)
$ / shares
shares
$0.93 - $2.00 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Number Outstanding (in Shares) | shares 2,872,922
Weighted Average Remaining Contractual Life (in Years) 8 years 5 months 15 days
Weighted Average Exercise Price $ 1.49
Number Exercisable (in Shares) | shares 1,564,467
Weighted Average Exercise Price $ 1.51
Aggregate Intrinsic value (in Dollars) | $ $ 369,936
$3.95 - $7.51 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Number Outstanding (in Shares) | shares 940,367
Weighted Average Remaining Contractual Life (in Years) 6 years 11 months 8 days
Weighted Average Exercise Price $ 5.29
Number Exercisable (in Shares) | shares 807,756
Weighted Average Exercise Price $ 5.46
Aggregate Intrinsic value (in Dollars) | $
$8.61 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Number Outstanding (in Shares) | shares 508,667
Weighted Average Remaining Contractual Life (in Years) 6 years 11 months 23 days
Weighted Average Exercise Price $ 10.53
Number Exercisable (in Shares) | shares 485,934
Weighted Average Exercise Price $ 10.53
Aggregate Intrinsic value (in Dollars) | $
$0.93 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Number Outstanding (in Shares) | shares 4,321,956
Weighted Average Remaining Contractual Life (in Years) 7 years 11 months 15 days
Weighted Average Exercise Price $ 3.38
Number Exercisable (in Shares) | shares 2,858,157
Weighted Average Exercise Price $ 4.16
Aggregate Intrinsic value (in Dollars) | $
Minimum [Member] | $0.93 - $2.00 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price $ 0.93
Minimum [Member] | $3.95 - $7.51 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 3.95
Minimum [Member] | $8.61 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 8.61
Minimum [Member] | $0.93 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 0.93
Maximum [Member] | $0.93 - $2.00 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 2
Maximum [Member] | $3.95 - $7.51 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 7.51
Maximum [Member] | $8.61 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price 17.7
Maximum [Member] | $0.93 - $17.70 [Member]  
Schedule of Outstanding and Exercisable Options [Line Items]  
Range of Exercise Price $ 17.7
v3.24.2.u1
Commitments and Contingencies (Details)
Jun. 30, 2024
USD ($)
Commitments and Contingencies [Line Items]  
Purchase obligations $ 768,000
Device Integration Agreement [Member]  
Commitments and Contingencies [Line Items]  
Purchase obligations $ 400,000
v3.24.2.u1
Related Party Transactions (Details) - USD ($)
 3 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Restricted Stock Units (RSUs) [Member]    
Related Party Transactions (Details) [Line Items]    
Company paid amount $ 57,300 $ 34,800
v3.24.2.u1
Subsequent Events (Details)
Aug. 02, 2024
shares
Subsequent Event [Member]  
Subsequent Events [Line Items]  
Outstanding options 242,307
Modular Medical (NASDAQ:MODD)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Modular Medical 차트를 더 보려면 여기를 클릭.
Modular Medical (NASDAQ:MODD)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Modular Medical 차트를 더 보려면 여기를 클릭.